Study of Verinurad in Heart Failure With Preserved Ejection Fraction

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 159 participants.

Also called NCT04327024

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 159 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04327024
  • EudraCT 2019-004862-16
Other papers using this trial's data
  • Verinurad Plus Allopurinol for Heart Failure With Preserved Ejection Fraction: The AMETHYST Randomized Clinical Trial JAMA cardiology, 2024-10-01 DOI, PubMed 39141378, PMC11325246 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Austria, Bulgaria, Canada, Germany, Mexico, Poland, Russia, Slovakia, South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04327024. Randomized; triple masking; primary purpose treatment. Start 2020-05-19 (actual); primary completion 2022-04-29 (actual). Results posted on 2023-06-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Verinurad in Heart Failure With Preserved Ejection Fraction
Acronym
AMETHYST
Intervention (Drug)
Verinurad
Intervention (Drug)
Allopurinol
Intervention (Drug)
Placebo for verinurad
Intervention (Drug)
Placebo for allopurinol
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct04327024
Content hash
d72023ef5ba73bf245057afac0f3416684e5d25221841dcb20ae82b70b3db6ee